IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)

Historical Holders from Q2 2017 to Q3 2025

Symbol
IOVA on Nasdaq
CUSIP
462260100
Type / Class
Equity / Common Stock
Shares outstanding
334M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
213M
Holdings value
$462M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
244
Number of buys
117
Number of sells
-112
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 7.5% $43.1M 25.1M The Vanguard Group Jun 30, 2025
BlackRock, Inc. 6.4% $36.6M 21.3M BlackRock, Inc. Jun 30, 2025
PERCEPTIVE ADVISORS LLC 3.8% -50% $45.6M -$33.1M 12.8M -42.1% Perceptive Advisors LLC Mar 31, 2025

Institutional Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 213M $462M -$12.4M $2.17 244
2025 Q2 220M $378M -$104M $1.72 244
2025 Q1 239M $798M -$41.5M $3.33 292
2024 Q4 242M $1.79B +$28.7M $7.40 294
2024 Q3 234M $2.2B +$19.3M $9.39 283
2024 Q2 232M $1.86B +$106M $8.02 290
2024 Q1 216M $3.2B +$204M $14.82 270
2023 Q4 207M $1.68B -$23.4M $8.13 235
2023 Q3 212M $965M -$1.2M $4.55 225
2023 Q2 204M $1.44B -$789K $7.04 215
2023 Q1 205M $1.25B +$199M $6.11 223
2022 Q4 173M $1.11B +$100M $6.39 211
2022 Q3 154M $1.48B -$54.9M $9.58 229
2022 Q2 156M $1.73B +$13.1M $11.04 227
2022 Q1 156M $2.59B -$16.4M $16.65 230
2021 Q4 156M $2.96B -$77.1M $19.09 236
2021 Q3 158M $3.88B -$126M $24.66 239
2021 Q2 162M $4.21B +$75.7M $26.02 229
2021 Q1 156M $4.95B +$228M $31.66 241
2020 Q4 149M $6.9B +$436M $46.40 270
2020 Q3 140M $4.61B -$20.1M $32.92 244
2020 Q2 141M $3.88B +$502M $27.45 257
2020 Q1 123M $3.67B -$30.1M $29.94 213
2019 Q4 124M $3.44B +$2.49M $27.68 197
2019 Q3 123M $2.25B +$952K $18.20 167
2019 Q2 122M $3B +$230M $24.52 164
2019 Q1 117M $1.11B -$11M $9.51 148
2018 Q4 119M $1.05B +$237M $8.85 135
2018 Q3 90.4M $1.02B +$78.6M $11.25 130
2018 Q2 83.2M $1.07B +$54.6M $12.80 125
2018 Q1 77.7M $1.31B +$341M $16.90 120
2017 Q4 57.6M $461M +$14.6M $8.00 86
2017 Q3 55.3M $429M +$59.8M $7.75 85
2017 Q2 47.6M $349M +$349M $7.35 82